Full text is available at the source.
Abstract
In March 2024, resmetirom received accelerated approval for treating adults with moderate to advanced liver fibrosis associated with noncirrhotic NASH in the USA.
- Resmetirom is an oral medication that acts as an agonist for the thyroid hormone receptor-β.
- The drug is aimed at addressing metabolic dysfunction linked to steatohepatitis.
- Approval was granted for use alongside diet and exercise in specific patient populations.
- Resmetirom is also undergoing regulatory review in the European Union for the same condition.
- The article outlines key milestones in the development of resmetirom leading to its approval.
Simplified